Alyeska Investment Group Portfolio holdings
AUM
$28.2B
1-Year Return
38.86%
This Quarter Return
-0.66%
1 Year Return
+38.86%
3 Year Return
+101.95%
5 Year Return
+160.93%
10 Year Return
+424.53%
AUM
$17.3B
AUM Growth
+$1.23B
(+7.7%)
Cap. Flow
+$1.46B
Cap. Flow
% of AUM
8.46%
Top 10 Holdings %
Top 10 Hldgs %
15.93%
Holding
670
New
184
Increased
139
Reduced
131
Closed
125
Top Buys
| 1 |
Qualcomm
QCOM
|
$289M |
| 2 |
Apple
AAPL
|
$263M |
| 3 |
Charles Schwab
SCHW
|
$200M |
| 4 |
Jabil
JBL
|
$166M |
| 5 |
Meta Platforms (Facebook)
META
|
$165M |
Top Sells
| 1 |
Alphabet (Google) Class A
GOOGL
|
$269M |
| 2 |
Oracle
ORCL
|
$244M |
| 3 |
Estee Lauder
EL
|
$172M |
| 4 |
Dell
DELL
|
$160M |
| 5 |
Microsoft
MSFT
|
$136M |
Sector Composition
| 1 | Technology | 24.84% |
| 2 | Consumer Discretionary | 14.31% |
| 3 | Healthcare | 13.75% |
| 4 | Industrials | 12.21% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Fulcrum Therapeutics
FULC
$414M
| $1.25M | 0.01% |
202,148
| – | – |
|
|
UBX
427
DELISTED
Unity Biotechnology
UBX
| $1.24M | 0.01% |
920,013
| – | – |
|
|
CMRC
428
Commerce.com, Inc. Series 1 Common Stock
CMRC
$361M
| $1.21M | 0.01% |
+150,000
| New | +$1.21M |
|
429
Alector
ALEC
$305M
| $1.16M | 0.01% |
256,182
| – | – |
|
|
BOLD
430
Boundless Bio
BOLD
$25.7M
| $1.16M | 0.01% |
300,000
+50,000
| +20% | +$194K |
|
|
BLRX
431
BioLineRX
BLRX
$15.6M
| $1.11M | 0.01% |
+48,834
| New | +$1.11M |
|
432
Urban Edge Properties
UE
$2.67B
| $1.08M | 0.01% |
+58,385
| New | +$1.08M |
|
433
Commault Systems
CVLT
$7.96B
| $1.07M | 0.01% |
+8,814
| New | +$1.07M |
|
434
Fastly
FSLY
$1.1B
| $1.06M | 0.01% |
143,965
-752,198
| -84% | -$5.54M |
|
435
Nautilus Biotechnolgy
NAUT
$83.5M
| $1.03M | 0.01% |
441,018
| – | – |
|
436
Ford
F
$46.7B
| $1.02M | 0.01% |
+81,621
| New | +$1.02M |
|
437
Hims & Hers Health
HIMS
$10.9B
| $1.01M | 0.01% |
+50,000
| New | +$1.01M |
|
|
TXNM
438
TXNM Energy, Inc.
TXNM
$5.99B
| $998K | 0.01% |
+27,000
| New | +$998K |
|
|
CLDT
439
Chatham Lodging
CLDT
$363M
| $987K | 0.01% |
+115,801
| New | +$987K |
|
440
Molson Coors Class B
TAP
$9.96B
| $959K | 0.01% |
18,864
-314,001
| -94% | -$16M |
|
441
Goosehead Insurance
GSHD
$2.11B
| $944K | 0.01% |
16,436
-205,213
| -93% | -$11.8M |
|
442
Dyne Therapeutics
DYN
$2.02B
| $882K | 0.01% |
+25,000
| New | +$882K |
|
443
Builders FirstSource
BLDR
$16.5B
| $869K | 0.01% |
6,279
-274,762
| -98% | -$38M |
|
|
BFS
444
Saul Centers
BFS
$812M
| $842K | ﹤0.01% |
22,911
-253,709
| -92% | -$9.33M |
|
|
VXRT
445
DELISTED
Vaxart
VXRT
| $834K | ﹤0.01% |
+1,250,000
| New | +$834K |
|
446
Lam Research
LRCX
$130B
| $832K | ﹤0.01% |
+7,810
| New | +$832K |
|
447
Cognition Therapeutics
CGTX
$230M
| $830K | ﹤0.01% |
500,000
| – | – |
|
448
A10 Networks
ATEN
$1.27B
| $810K | ﹤0.01% |
+58,453
| New | +$810K |
|
|
RAPP
449
Rapport Therapeutics
RAPP
$524M
| $808K | ﹤0.01% |
+34,731
| New | +$808K |
|
450
Adicet Bio
ACET
$60M
| $793K | ﹤0.01% |
655,665
| – | – |
|